Page last updated: 2024-11-13

duramycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

duramycin: from Streptomyces cinnamoneus; contains rare amino acids such as lanthionine & lysinoarginine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lancovutide : A 19-membered heterodetic cyclic peptide that is isolated from Streptoverticillium cinnamoneus. It exhibits antiproliferative properties and induces apoptosis in tumour cells and has been used for treatment of cystic fibrosis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID86289378
CHEBI ID77834
MeSH IDM0120637

Synonyms (3)

Synonym
duramycin
lancovutide
CHEBI:77834

Research Excerpts

Overview

Duramycin is a 19-amino-acid tetracyclic lantibiotic closely related to cinnamycin (Ro09-0198), which is known to bind phosphatidylethanolamine (PE) It has been shown to disrupt tumour cell surface-based coagulation and exhibit weak antimicrobial activity.

ExcerptReferenceRelevance
"Duramycin is a tetracyclic polypeptide that contains 19 amino acids and can bind to PE with excellent affinity and specificity."( Development of Duramycin-Based Molecular Probes for Cell Death Imaging.
Gao, M; Jiang, C; Jin, Q; Li, H; Ni, Y; Zhang, D; Zhang, J, 2022
)
1.8
"Duramycin is a heavily post-translationally modified peptide that binds phosphatidylethanolamine. "( Substrate-assisted enzymatic formation of lysinoalanine in duramycin.
An, L; Cogan, DP; Jiménez-Osés, G; Nair, SK; Navo, CD; van der Donk, WA, 2018
)
2.17
"Duramycin is a natural product produced by certain bacteria that binds to phosphatidylethanolamine (PE). "( Insights into the Biosynthesis of Duramycin.
Huo, L; Ökesli, A; van der Donk, WA; Zhao, M, 2017
)
2.18
"Duramycin is a small tetracyclic peptide which binds specifically to ethanolamine phospholipids (PE). "( Duramycin-induced destabilization of a phosphatidylethanolamine monolayer at the air-water interface observed by vibrational sum-frequency generation spectroscopy.
Backus, EH; Bonn, M; Kawai, M; Kobayashi, T; Rzeźnicka, II; Sovago, M; Yamada, T, 2010
)
3.25
"Duramycin is a polypeptide that binds specifically to phosphatidylethanolamine (PE) on cell surfaces with high affinity, and has been shown to disrupt tumour cell surface-based coagulation and exhibit weak antimicrobial activity. "( Duramycin exhibits antiproliferative properties and induces apoptosis in tumour cells.
Greenman, J; Madden, LA; Maraveyas, A; Udegbunam, NO; Welsh, J; Yates, KR, 2012
)
3.26
"Duramycin is a 19-amino-acid tetracyclic lantibiotic closely related to cinnamycin (Ro09-0198), which is known to bind phosphatidylethanolamine (PE). "( Curvature-dependent recognition of ethanolamine phospholipids by duramycin and cinnamycin.
Fujisawa, T; Hayakawa, T; Ito, K; Iwamoto, K; Kobayashi, T; Makino, A; Murate, M, 2007
)
2.02
"Duramycin is a polypeptide antibiotic (molecular weight 2012) obtained from culture filtrates of Streptomyces cinnamomeus forma azacoluta. "( Interaction of duramycin with artificial and natural membranes.
Aneja, R; Chabot, J; Navarro, J; Racker, E; Sherrill, K; Zahler, SA, 1985
)
2.06

Pharmacokinetics

duramycin was measured in the cellular fraction of bronchoalveolar lavage fluid (BALF) and brush biopsies. Researches have encouraged clinical evaluation of a few compounds, such as mutacin 1140.

ExcerptReferenceRelevance
"5 mg) of nebulized duramycin and underwent bronchoscopies to obtain a composite data set for pharmacokinetic analysis; duramycin was measured in the cellular fraction of bronchoalveolar lavage fluid (BALF) (mainly alveolar macrophages) and brush biopsies (bronchial epithelial cells)."( Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers.
Bauer, M; Errhalt, P; Freissmuth, M; Hinterberger, S; Holy, M; Hubner, M; Kneussl, M; Kubesch, K; Mascher, D; Müller, M; Steiner, I; Widmann, R, 2008
)
0.93
" Researches have encouraged clinical evaluation of a few compounds, such as mutacin 1140, microbisporicin, actagardine and duramycin, with pharmacokinetic profiles showing rapid distribution and elimination rates, good bioavailability and fecal excretion, as well as high protein binding."( Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies.
Neubauer, P; Ongey, EL; Pflugmacher, S; Yassi, H, 2017
)
0.66

Compound-Compound Interactions

ExcerptReferenceRelevance
" Group 1 received radiotherapy (RT, 15 Gy/mouse) in combination with cetuximab (CTX, 2 mg/mouse), group 2 received RT (15 Gy/mouse), group 3 was treated using CTX (2 mg/mouse), and group 4, the control group, was treated using a vehicle."( Early prediction of tumor response after radiotherapy in combination with cetuximab in nasopharyngeal carcinoma using
Cheng, J; Gray, B; Li, Y; Liu, C; Luo, J; Pak, KY; Qin, X; Xu, X; Yang, Z; Zhang, J; Zhang, Y, 2020
)
0.56
"We demonstrated that RT in combination with CTX treatment significantly improved disease control in a NPC xenograft model compared with monotherapy with either."( Early prediction of tumor response after radiotherapy in combination with cetuximab in nasopharyngeal carcinoma using
Cheng, J; Gray, B; Li, Y; Liu, C; Luo, J; Pak, KY; Qin, X; Xu, X; Yang, Z; Zhang, J; Zhang, Y, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" Researches have encouraged clinical evaluation of a few compounds, such as mutacin 1140, microbisporicin, actagardine and duramycin, with pharmacokinetic profiles showing rapid distribution and elimination rates, good bioavailability and fecal excretion, as well as high protein binding."( Pharmacological and pharmacokinetic properties of lanthipeptides undergoing clinical studies.
Neubauer, P; Ongey, EL; Pflugmacher, S; Yassi, H, 2017
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
heterodetic cyclic peptideA heterodetic cyclic peptide is a peptide consisting only of amino-acid residues, but in which the linkages forming the ring are not solely peptide bonds; one or more is an isopeptide, disulfide, ester, or other bond.
macrocycleA cyclic compound containing nine or more atoms as part of the cyclic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (15.07)18.7374
1990's10 (13.70)18.2507
2000's11 (15.07)29.6817
2010's34 (46.58)24.3611
2020's7 (9.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.26 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index82.29 (26.88)
Search Engine Supply Index3.93 (0.95)

This Compound (32.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.30%)5.53%
Reviews7 (9.09%)6.00%
Case Studies1 (1.30%)4.05%
Observational0 (0.00%)0.25%
Other68 (88.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]